Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019-03-26
|
| gptkbp:ATCCode |
L04AA45
|
| gptkbp:CASNumber |
1230487-00-9
|
| gptkbp:chemicalFormula |
C29H35F3N2O3
|
| gptkbp:contraindication |
severe hepatic impairment
recent myocardial infarction second-degree or higher AV block |
| gptkbp:drugClass |
immunotherapy
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:siponimod
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mayzent
|
| gptkbp:indication |
multiple sclerosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
sphingosine 1-phosphate receptor modulator
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
hypertension bradycardia liver enzyme elevation |
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|